Preserved supervised synthesis

Exenatide synthesis · version 1

This URL preserves the exact reviewed public wording and source set for synthesis version 1.

Supervised synthesis

What do selected human studies report about Exenatide?

Manually reviewed August 19, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

A bounded review of two randomized placebo-controlled trials in type 2 diabetes: one short monotherapy trial and one large cardiovascular-outcomes trial.21

Bottom line from this bounded source set

The short monotherapy trial reported improved glycated hemoglobin and weight measures. The larger outcomes trial established cardiovascular noninferiority but did not meet its superiority criterion for major cardiovascular events.21

Reviewed study record

Monotherapy trial

Design

A double-blind randomized placebo-controlled trial assessed glycemic measures, weight, and tolerability over 24 weeks.2

Population

The trial included 232 adults with type 2 diabetes that was inadequately controlled with diet and exercise and who had not used antidiabetic drugs.2

Outcomes reported

Mean glycated-hemoglobin reductions were 0.7 and 0.9 percentage points in the two exenatide groups and 0.2 points with placebo. Mean weight reductions were 2.8 and 3.1 kilograms versus 1.4 kilograms.2

Limitations

The trial was small and 24 weeks long, and its surrogate and weight outcomes do not establish longer-term clinical benefit or rare harms.2

Reviewed study record

EXSCEL cardiovascular-outcomes trial

Design

A sponsor-funded randomized placebo-controlled cardiovascular-outcomes trial followed participants for a median of 3.2 years alongside usual care.1

Population

The trial randomized 14,752 adults with type 2 diabetes; 73.1% had previous cardiovascular disease.1

Outcomes reported

The primary cardiovascular outcome occurred in 11.4% of the exenatide group and 12.2% of the placebo group. The comparison met noninferiority for safety but not superiority for efficacy.1

Limitations

The pragmatic trial included participants with and without prior cardiovascular disease, and its borderline superiority result should not be reframed as proof of cardiovascular benefit.1

Reviewed source set

  1. PubMed · 28910237Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes ↗PubMed PMID 28910237 · EFetch XML reviewed 2026-08-19 · payload SHA-256 63ec335a3a836425cbeda76243629bf58816c0c94abb17e82892e75e64dd09ce
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1056/nejmoa1612917. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 18803987Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study ↗PubMed PMID 18803987 · EFetch XML reviewed 2026-08-19 · payload SHA-256 46630cea7e348965315f0b3262be9855bfc819b39a67396e405cd68462493e1e
    No registered Crossref update in the reviewed snapshotChecked August 19, 2026 for DOI 10.1016/j.clinthera.2008.08.006. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗